This review focuses on the most widely used methods for measuring BCF within thecontext of insulin resistance and includes examples of their use in prediabetes and T2DM, with an emphasis on the mostrecent therapeutic options (dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists). The gene discussed is GLP1R; the disease is prediabetes syndrome.